Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

Recruiting

DupilumabPost-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT04173442

Conditions

Atopic Dermatitis (AD)

Asthma

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Interventions

dupilumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-22. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2025-05-30.